Kinetics of lymphokine production in HIV+ patients treated with highly active antiretroviral therapy and interleukin 2

Paolo De Paoli, Stefania Zanussi, Laura Caggiari, Maria Teresa Bortolin, Monica D'Andrea, Cecilia Simonelli, Umberto Tirelli

Research output: Contribution to journalArticle

Abstract

This study presents the kinetics of CD4/CD25 cell numbers, serum sCD25 levels, and intracellular production and release of interleukin-2 (IL-2) and interleukin-16 (IL-16) in 11 HIV+ patients treated with six cycles of highly active antiretroviral therapy (HAART) plus six MUI of subcutaneous IL-2 compared to 10 HIV+ patients treated with HAART alone. IL-2 therapy induced moderate effects on CD4 T cell recovery and increased CD4/CD25+ cells and sCD25 levels after 2 weeks, while intracellular and secreted IL-2 was reduced and IL-16 was increased at the same time point. After 24 weeks, while HAART- treated patients had increased IL-2 production, in IL-2 treated patients, cytokine production was unaltered compared to pretreatment values: Decreased in vitro IL-2 production may depend on a feedback inhibition by IL-2 infusion. Because of its known antiviral effects, the increased IL-16 production seen after 2 weeks in IL-2-treated individuals may produce beneficial effects on HIV disease. The kinetics of cytokine production may serve to define better the use IL-2 in clinical trials.

Original languageEnglish
Pages (from-to)317-325
Number of pages9
JournalJournal of Clinical Immunology
Volume19
Issue number5
DOIs
Publication statusPublished - 1999

Keywords

  • Highly active antiretroviral therapy
  • HIV infection
  • IL-16
  • IL-2 production
  • IL-2 therapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Kinetics of lymphokine production in HIV+ patients treated with highly active antiretroviral therapy and interleukin 2'. Together they form a unique fingerprint.

Cite this